-
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa Hopledo® is already approved and marketed in the United States as CREXONT®, providing established regulatory and commercial experience as the therapy advances toward European approval More than…
-
This Pharmacy Chain is Saving India INR 300 Cr a Year – And You've Probably Never Heard of It
In India’s complex and expensive healthcare ecosystem, where sufferers still consume a significant portion of their income on pharmaceuticals, a quiet transformation is ongoing. While digital health startups often lead headlines, one drugstore chain is leading a hidden but impactful transformation. Medkart, based in Gujarat and focused solely on generic medicines, is helping Indian households…
-
Akums Reports Q2 FY26 Results; Strengthens International Presence
New Delhi, Delhi, India Akums Drugs & Pharmaceuticals Ltd., India’s Largest Contract Development and Manufacturing Organizations (CDMO), announced its financial results for the second quarter of FY26. The CDMO segment remained the key contributor with revenue of Rs. 804 crore. Volumes for the CDMO vertical grew 7% y-o-y, as against muted industry volume growth, reflecting…
-
Akums Delivers Strong Q3 FY26 Performance with 14.8% Revenue Growth and 21% Adj EBITDA Growth
New Delhi, Delhi, India Akums Drugs & Pharmaceuticals Ltd., India’s Largest Contract Development and Manufacturing Organizations (CDMO), announced its financial results for the third quarter of FY26. Q3 FY 26 saw strong performance across its key business segments. CDMO saw a revenue growth of over 16% spurred on by double digit increase in volumes. The…
-
Akums Reports Q4 FY26 and Full Year FY26 Results with Healthy Top Line and Strong EBITDA Growth; Board Recommends Dividend
New Delhi, Delhi, India Akums Drugs & Pharmaceuticals Ltd., India’s largest Contract Development and Manufacturing Organisation (CDMO), announced its financial results for the fourth quarter and the full year ended March 31, 2026. The company delivered a steady performance during Q4 FY26, with healthy revenue growth and improved operating profitability driven by its core domestic…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
